Direct Xa inhibitor

Jump to: navigation, search

WikiDoc Resources for Direct Xa inhibitor

Articles

Most recent articles on Direct Xa inhibitor

Most cited articles on Direct Xa inhibitor

Review articles on Direct Xa inhibitor

Articles on Direct Xa inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Direct Xa inhibitor

Images of Direct Xa inhibitor

Photos of Direct Xa inhibitor

Podcasts & MP3s on Direct Xa inhibitor

Videos on Direct Xa inhibitor

Evidence Based Medicine

Cochrane Collaboration on Direct Xa inhibitor

Bandolier on Direct Xa inhibitor

TRIP on Direct Xa inhibitor

Clinical Trials

Ongoing Trials on Direct Xa inhibitor at Clinical Trials.gov

Trial results on Direct Xa inhibitor

Clinical Trials on Direct Xa inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Direct Xa inhibitor

NICE Guidance on Direct Xa inhibitor

NHS PRODIGY Guidance

FDA on Direct Xa inhibitor

CDC on Direct Xa inhibitor

Books

Books on Direct Xa inhibitor

News

Direct Xa inhibitor in the news

Be alerted to news on Direct Xa inhibitor

News trends on Direct Xa inhibitor

Commentary

Blogs on Direct Xa inhibitor

Definitions

Definitions of Direct Xa inhibitor

Patient Resources / Community

Patient resources on Direct Xa inhibitor

Discussion groups on Direct Xa inhibitor

Patient Handouts on Direct Xa inhibitor

Directions to Hospitals Treating Direct Xa inhibitor

Risk calculators and risk factors for Direct Xa inhibitor

Healthcare Provider Resources

Symptoms of Direct Xa inhibitor

Causes & Risk Factors for Direct Xa inhibitor

Diagnostic studies for Direct Xa inhibitor

Treatment of Direct Xa inhibitor

Continuing Medical Education (CME)

CME Programs on Direct Xa inhibitor

International

Direct Xa inhibitor en Espanol

Direct Xa inhibitor en Francais

Business

Direct Xa inhibitor in the Marketplace

Patents on Direct Xa inhibitor

Experimental / Informatics

List of terms related to Direct Xa inhibitor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Direct factor Xa inhibitors ('xabans') are a class of anticoagulant drugs which act directly upon Factor X in the coagulation cascade, without using antithrombin as a mediator.[1]

Clinical uses

Direct factor Xa inhibitors are being used clinically. Clinical trials have shown promise for these compounds as substitutes for the currently administered vitamin K antagonists or low molecular weight heparin. Advantages of orally administered direct Xa inhibitors lie in the fact that they have a predictable effect, do not require frequent monitoring or re-dosing, are given through the mouth and not by injection and have few (known) drug interactions. Disadvantages include the currently limited prospective experience and lack of specific antidotes (although research in that field is ongoing, andexanet alfa being a candidate antidote).

Examples

A naturally occurring inhibitor of factor Xa was first reported in 1987. Tuszynski et al. discovered antistasin, which was isolated from the extracts of Mexican leech, Haementeria officinalis. Soon after this, another naturally occurring inhibitor, tick anticoagulant peptide (TAP) was isolated from the extract of tick Ornithodoros moubata.

Examples include:

References

  1. "Medscape.com". Retrieved 2009-01-23.
  2. Turpie AG (June 2007). "Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases". Arterioscler. Thromb. Vasc. Biol. 27 (6): 1238–47. doi:10.1161/ATVBAHA.107.139402. PMID 17379841.
  3. Cohen M, Bhatt DL, Alexander JH; et al. (May 2007). "Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial". Circulation. 115 (20): 2642–51. doi:10.1161/CIRCULATIONAHA.106.653428. PMID 17502577.
  4. Paccaly A, Ozoux ML, Chu V; et al. (December 2005). "Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor". Thromb. Haemost. 94 (6): 1156–63. doi:10.1160/TH05-05-0347. PMID 16411387.
  5. Eriksson BI, Borris LC, Dahl OE; et al. (November 2006). "A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement". Circulation. 114 (22): 2374–81. doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766.

External links


Linked-in.jpg